Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 459-270-7 | CAS number: 2568-33-4 MBD
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2022-10-14 to 2023-xx-xx
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 023
- Report date:
- 2023
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 3-methyl-1,3-butandiol
- EC Number:
- 459-270-7
- EC Name:
- 3-methyl-1,3-butandiol
- Cas Number:
- 2568-33-4
- Molecular formula:
- C5 H12 O2
- IUPAC Name:
- 3-methylbutane-1,3-diol
Constituent 1
- Specific details on test material used for the study:
- Test item name as stated in the report: 3-methyl-1,3-butanediol
Alternate Identification: Isopentyldiol
SOURCE OF TEST MATERIAL
- Source: Kuraray Co., Ltd., Otemachi, Chiyoda-ku, Tokyo (Japan)
- Sponsor and lot/batch number of test material: 23515
- Purity (GC): ≥99.9%
- Expiration Date: 02 December 2023
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Controlled room temperature (up to 25.38°C) protected from light, humidity and under nitrogen purge
- Stability and homogeneity of the test material in the vehicle/solvent under test conditions (e.g. in the exposure medium) and during storage: Stability analyses performed previously in conjunction with Study No. 20384993 demonstrated that the test item formulation is stable when prepared and stored under the same conditions as those used in the present study (In a concentration range of 10–120 mg/mL for at least 8 days at room temperature and +4°C and for at least 3 weeks at -20°C).
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
Dosing formulations were prepared at appropriate concentrations in purified water as vehicle to meet dose level requirements according to standard operating procedures of the Test Facility.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Wistar Han IGS
- Details on species / strain selection:
- The rat was chosen as the animal model for this study as it is an accepted rodent species for preclinical toxicity testing by regulatory agencies.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories France, 327 Impasse du Domaine Rozier, Les Oncins, 69210 Saint-Germain-Nuelles, France
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: males: 10 weeks, females: 11 weeks
- Weight at study initiation: Males: 315 - 368 g; Females: 187 - 261g
- Fasting period before study: no
- Housing: group housed during pre-mating period (up to 4 for males and 5 females), 1 male and 1 female housed together during mating, after mating males were group-housed (up to 4) and females single housed with litter up to lactation period in plastic cage containing appropriate bedding. For psychological/environmental enrichment, animals were provided with items such as a wooden gnaw block and shredded paper, except when interrupted by study procedures/activities. It was considered that there were no known contaminants in the enrichment that could have interfered with the outcome of the study.
- Diet: ad libitum, complete rodent diet (Reference No. SM-VRF1-C12), sterilized by irradiation
- Water: ad libitum, softened and filtered (0.2 µm) municipal drinking water.
- Acclimation period: 21 days and 7 days before the start of dosing for females and males, respectively.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25
- Humidity (%): ≥ 35
- Air changes (per hr): ≥ 10 per hour
- Photoperiod (hrs dark / hrs light):12/12
IN-LIFE DATES: From: 2022-11-07 To: 2023-01-02
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- OTEC H2O sterile water for technical use
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Dosing formulations were prepared at appropriate concentrations to meet dose level requirements according to standard operating procedures of the Test Facility
VEHICLE
- Amount of vehicle (if gavage): 10 mL
- Lot/batch no. (if required): C0822 - Details on mating procedure:
- - M/F ratio per cage:1/1
- Length of cohabitation: for a maximum of 14 days
- Proof of pregnancy: presence of sperm in a vaginal smear or a vaginal plug referred to as day 0 of pregnancy
- After unsuccessful pairing replacement of first male by another male with proven fertility/Further matings after two unsuccessful attempts: Not necessary, all pairs of rats mated within the designated mating period.
- After successful mating each pregnant female was caged (how): single - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analyses were performed by gas chromatography (GC) method using a validated analytical procedure (Test Facility Study No. 20384993).
All analyzed samples for formulations prepared at nominal concentrations of 12, 35 and 100mg/mL of 3-methyl-1, 3-butanediol in vehicle "purified water" taken from each preparation used for dosing on the first day of treatment were within the acceptance criteria (± 10%). Furthermore the test item prepared as a solution in the vehicle was homogenous as the RSD on the six aliquots (Top, Middle, Bottom) was ≤ 1%. Finally, no test item was present in the vehicle sample. - Duration of treatment / exposure:
- Males: from 14 days before mating, throughout mating and up to the day before necropsy (i.e., 35 days)
Females: from 14 days before mating, throughout mating, gestation and lactation and up to the day before necropsy (i.e., LD13-15). - Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 120 mg/kg bw/day (nominal)
- Dose / conc.:
- 350 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels (0, 120, 350, and 1000 mg/kg/day) were selected in the present study in conjunction with the Sponsor, based on a 28-day oral toxicity study according to OECD guideline 407. In this study, dose levels of 0, 15, 150, and 1000 mg/kg/day were administered by daily oral gavage to Wistar rats. No treatment related effects were observed up to the highest dose level. A no observed adverse effect level (NOAEL) of 1000 mg/kg/day was determined in this study.
- Fasting period before blood sampling for clinical biochemistry: no - Positive control:
- no
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Before and at least once after dosing. At least once daily on non-dosing days (The pre-dose clinical observation was not performed on Day 16 for all animals and on Day 23 for Male Nos. 1001 to 1007, in error. As no clinical signs were observed after dosing, this deviation was considered to have had no impact on the study outcome.)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: A full clinical examination was performed on each weighing day
BODY WEIGHT: Yes
- Time schedule for examinations: All females: weekly during pre-mating and mating (only pre-mating data are reported), then on GD0, GD4, GD7, GD11, GD14, GD17, GD20,LD1, LD4, LD7, and LD13. All males: once pretest and then weekly from Day 1
FOOD CONSUMPTION
All females: Weekly during pre-mating (from Day 1), then on GD0 to 4, 4 to 7, 7 to 11, 11 to 14, 14 to 17 and 17 to 20, and on LD1 to 4, 4 to 7 and 7 to 13 (On 06 Dec 2022, the food consumption values of all females were found to be negative, most probably following a food distribution error without associated data recording. As a consequence, these aberrant values were excluded from the mean calculations and statistical analysis for the periods GD7 to GD11 or GD11 to GD14 and GD0 to GD20. This loss of data had no impact on the study outcome since there was no change in food consumption that affected body weight gain in any group).
All males: Weekly during premating (from Day 1)
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No - Oestrous cyclicity (parental animals):
- Estrous cycles: daily from 2 weeks before treatment, the first 2 weeks of treatment and until identification of mating or separation from the male. Vaginal smear taken on the day of scheduled necropsy.
- Sperm parameters (parental animals):
- Parameters examined in male parental generation of Groups 1 (control) and 4 (high dose) and for macroscopic lesions from all dose groups:
testis weight, epididymis weight, For the testes from all adult males of Groups 1 (control) and 4 (high dose) and all males suspected to be infertile, in addition to the haematoxylin and eosin-stained slide, an additional slide was prepared and examined, stained with PAS. A detailed, qualitative evaluation of the testes was made, taking into account the tubular stages of the spermatogenic cycle. The cell- or stage-specificity of any testicular findings was recorded, where appropriate. - Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- If yes, maximum of 8 pups/litter (random selection of 4/sex/litter, if possible); excess pups were killed and discarded.
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: number of pups born (live and dead), external abnormalities of the pups, number, weight and sex of pups alive on PND1, 4, 7, 10 and 13, anogenital Distance (AGD) was measured on PND1 and normalized to the cube root of body weight. All males in each litter were examined for the number of areola/nipples on PND13.
Blood samples were collected from at least 2 of the surplus pups (if possible from 1 male and 1 female pup) from all litters culled on PND4 and 2 pups per litter where possible on PND13 or 15 used for determination of serum T4 and possibly TSH levels.
GROSS EXAMINATION OF DEAD PUPS: yes. Pups (including those found dead) were necropsied and submitted to a full external macroscopic examination and examination of the abdominal and thoracic cavities. Any
abnormalities observed were recorded but not preserved. For pups found dead, the stomach was examined and the absence of milk was recorded if applicable, and defects or cause of death were evaluated if possible.
Each pup was sexed and examined for external defects with special attention being paid to the external reproductive organs. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals
- Maternal animals: All surviving animals
GROSS NECROPSY
- All animals (including the female with total litter death) were submitted to necropsy procedures including an examination of the following: external surface, all orifices, cranial cavity, thoracic and abdominal cavities and organs and their contents, the carcass.
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table 1 in section "Any other information on materials and methods incl. tables" were prepared for microscopic examination and weighed, respectively. - Postmortem examinations (offspring):
- SACRIFICE/GROSS NECROPSY
- The F1 offspring not selected were sacrificed at 4 days of age (PND 4).
- These animals were subjected to postmortem examinations (macroscopic and/or microscopic examination) as follows: Full external macroscopic examination and examination of the abdominal and thoracic cavities. Any abnormalities observed were recorded but not preserved. For pups found dead, the stomach was examined and the absence of milk was recorded if applicable, and defects or cause of death were evaluated if possible. Each pup was sexed and examined for external defects with special attention being paid to
the external reproductive organs.
HISTOPATHOLOGY / ORGAN WEIGTHS: no - Statistics:
- Descriptive Statistical Analyses:
Means, standard deviations (or % coefficient of variation or standard error, when deemed appropriate), percentages, numbers, and/or incidences were reported, as appropriate by dataset.
Inferential Statistical Methods:
All statistical tests were conducted at the 5% significance level. All pairwise comparisons were conducted using two-sided tests and were reported at the 1% and 5% levels, unless otherwise noted.The pairwise comparisons of interest are listed below:
Group 2 vs. Group 1
Group 3 vs. Group 1
Group 4 vs. Group 1
Analyses were performed according to the matrix shown in table 2 below in section "Any other information on materials and methods incl. tables" when possible, but excluded any group with less than 3 observations.
Parametric/Non-Parametric:
Levene’s test was used to assess the homogeneity of group variances. The groups were compared using an overall one-way ANOVA F-test if Levene’s test is not significant or the Kruskal-Wallis test if it was significant. If the overall F-test or Kruskal-Wallis test was found to be significant, then pairwise comparisons were conducted using Dunnett’s or Dunn’s test, respectively.
Non-Parametric:
The groups were compared using an overall Kruskal-Wallis test. If the overall Kruskal-Wallis test was found to be significant, then the above pairwise comparisons were conducted using Dunn’s test.
Incidence:
A Fisher’s exact test was used to conduct pairwise group comparisons of interest. - Reproductive indices:
- The following reproductive indices were included
Pre-Coital Interval (Days): (Sum of days until successful insemination/Number of inseminated females) *100
Female Mating Index (%): (Number of females with evidence of mating/ Number of paired females) *100
Female Fertility Index (%): (Number of pregnant females/ Number of females with evidence of mating) *100
Gestation Index (%): (Number of females with live pups/ Number of pregnant females) *100 - Offspring viability indices:
- Post Implant Loss/Litter (%): ((Number of implantations-Number of pups born)/Number of implantations)*100
Live Birth Index (%) :(Number of pups born alive/ Number of pups born) *100
Viability Index (%) :(Number of pups alive on PND4/ Number of pups alive at birth) *100
Lactation Index (%): Number of pups alive on PND 13/ Number of pups alive on PND 4)*100
Sex ratio (%): (Number of live male pups/ Total number of live pups)*100
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There was no test item-related clinical sign in any group for either sex.
Clinical signs such as salivation, slight locomotor stereotypy, bent tail, scabs, thin fur cover or stained fur, and/or soft feces were noted sporadically across groups (including control) and were considered incidental. - Mortality:
- no mortality observed
- Description (incidence):
- There was no test item-related death in any group.
One female from the 120 mg/kg/day group was euthanized on LD1 following total litter death. - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There was no test item-related effect on mean body weight gain and mean body weight throughout the dosing period for the males and during the premating, gestation and lactation periods for the females in any group (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”).
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There was no test item-related effect on mean food consumption during the premating period in any group for either sex.
There was no obvious test item-related effect on mean food consumption during the gestation and lactation periods in any group for the females.
Minor variations were observed during the gestation period. Despite some differences that attained statistical significance, there was no trend or correlated data that suggested that these variations were test item-related. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- There was no test item-related effect on mean T4 concentration in adult males (for more information, please refer to section "Any other information on results inlc. tables").
- Endocrine findings:
- no effects observed
- Description (incidence and severity):
- There were no test item-related effects on thyroid hormones in male rats, nor any other effects with regard to endocrine-related mode of actions on estrous cycles in female rats or organ weights and histopathology in adult rats of any dose group.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No test item-related microscopic findings were noted. The microscopic findings observed were considered incidental, of the nature commonly observed in this strain and age of Wistar Han rat, and/or were of similar incidence and severity in control and treated animals and, therefore, were considered unrelated to treatment.
- Histopathological findings: neoplastic:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- There was no test item-related effect on estrous cyclicity in any group.
Mean length and regularity of the estrous cycles were comparable in all groups during the acclimatization and treatment periods (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”). - Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- All pairs of rats mated in the control, 120, 350 and 1000 mg/kg/day groups. The mating index was therefore 100% in all groups.
All mated females were inseminated within the first 4 days of pairing (approximate duration of a normal estrous cycle). The mean pre-coital interval was therefore comparable (less than 4 days) in all groups.
All mated females became pregnant in all groups except 1 in the 120 mg/kg/day group. This isolated case in the low dose group was incidental.
All pregnant females in the control, 120, 350, and 1000 mg/kg/day groups successfully completed delivery of liveborn pups. The mean duration of gestation was comparable in all groups (21.8 to 21.9 days) (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”).
Effect levels (P0)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed
Target system / organ toxicity (P0)
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There was no pattern in the incidence of pup clinical observations that suggested any association with maternal treatment.
Consistent with the total litter loss of one female from the 120 mg/kg/day group, there was a higher incidence of pups with no milk band present in the 120 mg/kg/day group compared with the control group. - Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- There was no effect of maternal treatment on pup viability and litter size.
The live birth and viability indices (88.7% and 87.2%, respectively) in the 120 mg/kg/day group were slightly lower compared with the control group (97.3% and 100%, respectively).
These mean group values were disproportionately influenced by one female from the 120 mg/kg/day group, which delivered 10 stillborn pups out of 12 newborn pups and subsequently lost the 2 live pups. In the absence of similar case in the higher dose groups, this isolated finding in the low dose group was considered incidental.
The survival index was 100% in all groups (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”). - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There was no effect of maternal treatment on mean pup body weight in any group for either sex (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”).
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- There was no test item-related effect on mean T4 concentration in PND13 pups (male and female) in any group (for more information, please refer to section "Any other information on results inlc. tables").
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Anogenital distance (AGD):
- no effects observed
- Description (incidence and severity):
- The mean normalized anogenital distance was slightly but statistically significantly longer for the males in the 350 and 1000 mg/kg/day groups compared with the concurrent control group. However, all values fell within the historical control range, so the differences were considered to be of no toxicological significance (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”).
- Nipple retention in male pups:
- no effects observed
- Description (incidence and severity):
- No nipples were observed for the male offspring examined on PND13 in any group (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”).
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No test item-related gross findings were noted. The gross findings observed were considered incidental, of the nature commonly observed in this strain and age of Wistar Han rat, and/or were of similar incidence in control and treated animals and, therefore, were considered unrelated to treatment.
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- The mean number of implantation and percentage pre-birth (post-implantation) loss in treated groups were comparable with the control group.
There was no effect of maternal treatment on sex ratio in any group (for more information, please refer to attached detailed tabular summary in section “Overall remarks, attachments”).
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed
Target system / organ toxicity (F1)
- Critical effects observed:
- no
Overall reproductive toxicity
- Reproductive effects observed:
- no
Any other information on results incl. tables
Table 1. Mean Thyroid Hormone Concentrations for F0 males on the Day of Necropsy and F1 male and female Pups on PND13-15
Group Number | Dose Level (mg/kg/day) |
Values | F0 Males on the Day of Necropsy | F1 Male Pups on PND13-15 | F1 Female Pups on PND13-15 |
T4 (ng/mL) |
T4 (ng/mL) |
T4 (ng/mL) |
|||
1 | 0 | MEAN | 46.0 | 53.1 | 51.8 |
SD | 6.3 | 6.1 | 5.1 | ||
N | 10 | 10 | 10 | ||
2 | 120 | MEAN | 45.5 | 52.1 | 52.4 |
SD | 4.6 | 7.2 | 6.1 | ||
N | 10 | 8 | 8 | ||
3 | 350 | MEAN | 47.9 | 51.6 | 49.2 |
SD | 7.0 | 6.1 | 3.7 | ||
N | 10 | 10 | 10 | ||
4 | 1000 | MEAN | 45.3 | 51.4 | 50.0 |
SD | 6.0 | 3.3 | 3.4 | ||
N | 10 | 10 | 10 |
Applicant's summary and conclusion
- Conclusions:
- No adverse effects were observed reproduction/developmental toxicity screening test (OECD 421, GLP) conducted in Wistar Han IGS rats. The NOAEL is at least 1000 mg/kg bw/day for systemic, reproductive, and developmental toxicity.
- Executive summary:
In a reproduction/developmental toxicity screening test (OECD 421, GLP), 3-methyl-1,3-butanediol (purity 99.9%) was administered to 10 Wistar Han IGS rats/ sex/dose by daily gavage at dose levels of 0, 120, 350, 1000 mg/kg bw/day. The test item was administered to males from 14 days before mating, throughout mating and up to the day before necropsy (i.e., 35 days). It was administered to females from 14 days before mating, throughout mating, gestation and lactation and up to the day before necropsy (i.e., lactation day (LD) 13-15).
There were no test item related effects on mortality, clinical signs, body weights, body weight gains, food consumption, estrous cycles, reproductive performance for the F0 Generation. No effects were observed during paternal and maternal gross necropsy investigations, on organ weights and microscopic observations.
No treatment related effects were observed on pups viability and litter sizes, weight and sex of pups, and physical developmental landmarks of pups (anogenital distance and nipple retention in males). There was no test item-related change in T4 concentration in adult males and in post natal day (PND) 13 pups of either sex in any group.
The NOAEL is at least 1000 mg/kg bw/day for systemic, reproductive, and developmental toxicity.
This study is acceptable and satisfies the guideline requirement for a OECD 421.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.